Design and uses of a novel diabetes immunoloregulation peptide-VP peptide

A technology for diabetes and diabetes drugs, applied in the fields of pharmacy and medicine, can solve problems such as vascular endothelial cell damage, and achieve the effects of reducing the level of insulitis, controlling blood sugar levels, and maintaining normal secretion function.

Active Publication Date: 2017-03-22
CHINA PHARM UNIV
View PDF2 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] However, there are also literatures showing that heat shock protein 60 (Heat shock protein, Hsp60) can also bind to TLR4 on vascular endotheli...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Design and uses of a novel diabetes immunoloregulation peptide-VP peptide
  • Design and uses of a novel diabetes immunoloregulation peptide-VP peptide
  • Design and uses of a novel diabetes immunoloregulation peptide-VP peptide

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0026] Example 1: Evaluation of side effects of VP peptide atherosclerosis

[0027] 1. Breeding and immunization of New Zealand white rabbits

[0028] New Zealand white rabbits were divided into two groups according to different feeding conditions, 24 in the low-fat group (LCD) and 24 in the high-fat group (HCD). The low-fat group was always fed with common feed, and the high-fat group was fed with high-fat feed until the end of the experiment. The formula of high-fat feed is to add 1% cholesterol, 6% lard and 10% egg yolk powder on the basis of ordinary rabbit feed. The two groups were divided into four groups: PBS group, P277 group, VP group and AP group, with 6 rats in each group. Animals in each group were immunized for the first time from the zeroth week, and were immunized four times in total, with an interval of 4 weeks between the two times. Dissolve P277 / VP / AP in sterile PBS at a concentration of 1 mg / mL. CFA was used as an adjuvant for the first immunization, and ...

Embodiment 2

[0034] Example 2: Evaluation of diabetes-related pharmacodynamics of VP peptide

[0035] 1. Animal immunity

[0036] Twenty-five 4-week-old female NOD / LtJ mice were randomly divided into 4 groups, AP group, VP group, P277 group (positive control) and oil group (blank control). From the 5th week of NOD, the drug was administered subcutaneously in the neck every two weeks, for a total of 3 times, respectively at the 5th, 7th, and 9th week. Before administration, the polypeptide was dissolved in Libaofatine at 1 mg / mL, and the dosage was 80 μg / head.

[0037] 2. Effects on body weight and blood sugar of NOD mice

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

A novel diabetes-related immunoloregulation vaccine peptide VP is designed which can effectively prevent T1DM attack and is free of an atherosclerotic side effect. The VP peptide does not cause lipid disorders in serum of mice, sharp hs-CRP level increases or atherosclerosis side effects. The VP peptide can control blood glucose of NOD mice, maintain normal body weights of mice and reduce the incidence of T1DM. In addition, the VP peptide can maintain normal secretion functions of islet beta cells and can allow the cells to exert normal blood sugar adjusting functions.

Description

technical field [0001] The present invention relates to the fields of pharmacy and medicine, in particular to the prevention and treatment of diabetes; more specifically, the present invention relates to a class of novel peptides and their uses, as well as pharmaceutical preparations containing the novel peptides and their derivatives and analogs, capable of For the prevention and treatment of human diabetes. Background technique [0002] Type 1 diabetes mellitus (T1DM) usually manifests as pancreatitis (infiltration of mononuclear cells around the islets), necrosis or reduction of β cells (positively correlated with the time of onset) or expression of inflammatory factors. T1DM is mainly caused by the disorder of the autoimmune system. The expansion of autoreactive T cells and autoantigen-activated B cells activates the autoimmune system to attack pancreatic β cells, resulting in insufficient insulin secretion. Self-antigen immunization can interfere with the reaction of M...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07K14/00A61K38/17A61P3/10
Inventor 金亮卢世平高华山吴洁张艳峰
Owner CHINA PHARM UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap